Lip cancer: lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Screening, prevention and diagnosis	1
Early / localised	1
Advanced, first line	1
Other settings	1

Screening, prevention and diagnosis

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Prevention	Sun protection of the lips, smoking cessation, and treatment of actinic cheilitis.	Smoking cessation in cancer patients		32

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Early disease	Wedge or V excision with local flap reconstruction, or radiotherapy (external beam or brachytherapy) for commissure tumours or unfit patients.	IMRT / IGRT (modern external beam)Brachytherapy	NCCN · Category 2A	93

Advanced, first line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Unresectable or metastatic	Cemiplimab as for cutaneous squamous cell carcinoma, or pembrolizumab-based treatment as for head and neck squamous cell carcinoma.	CemiplimabPembrolizumabKEYNOTE-048	NCCN · Category 2A	98

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Large, thick or node-positive disease	Resection with flap reconstruction, sentinel node biopsy or neck dissection, and postoperative radiotherapy; cisplatin for extranodal extension or positive margins.	IMRT / IGRT (modern external beam)Sentinel lymph node biopsyCisplatinChemoradiation (chemoradiotherapy, CRT)	NCCN · Category 2A	93

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.